What patients think and understand can impact their decisions and their outcomes

It has long been appreciated that African-American males have higher risk for diagnosis with prostate cancer, and higher risk for prostate cancer-specific mortality, than those of other ethnic origins living in the US. … READ MORE …

Can RP + EBRT + ADT provide equal outcomes to brachy boost therapy + ADT in high-risk men?

As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone or external beam radiation therapy (EBRT) alone. … READ MORE …

The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …

Prostate cancer outcomes today vs. outcomes yesteryear

As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. … READ MORE …

Early data from the PROPS imaging trial prior to SRT

A recent presentation by Pouliot Frederick, MD, at the annual meeting of the Canadian Urological Association in Halifax, Nova Scotia, provided information on the roles of multiparametric MRI, [18F]choline, and 86Ga-PSMA PET/CT scans in determining the utility and value of salvage radiation therapy (SRT) for patients progressing after first-line surgery. … READ MORE …

Speed of change in the management of prostate cancer

One of our regular correspondents (who lives in England) was recently told something rather interesting by the Consultant Urologist he sees in the UK. … READ MORE …

FDA approves use of enzalutamide (Xtandi) for nmCRPC

As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), … READ MORE …